Quoin Pharmaceuticals, Ltd.

Stocks

QNRX

US74907L4095

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:51:05 09/06/2026 BST			5-day change	1st Jan Change
4.635 ^USD	+1.42%		+3.07%	-67.43%

06-04	Quoin Pharmaceuticals' Skin Disorder Drug Receives Orphan Drug Designation in Japan	MT
06-02	Quoin Pharmaceuticals Submits Ind Application for Qrx003 in Peeling Skin Syndrome	CI

Quoin Pharmaceuticals, Ltd. Auditor Raises 'Going Concern' Doubt

Published on 03/25/2026

S&P Capital IQ

QUOIN PHARMACEUTICALS, LTD.

+1.42%

Quoin Pharmaceuticals, Ltd. filed its 10-K on Mar 26, 2026 for the period ending Dec 31, 2025. In this report its auditor, CBIZ CPAs P.C, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Quoin Pharmaceuticals, Ltd.

06-04	Quoin Pharmaceuticals' Skin Disorder Drug Receives Orphan Drug Designation in Japan	MT
06-02	Quoin Pharmaceuticals Submits Ind Application for Qrx003 in Peeling Skin Syndrome	CI
06-02	Quoin Pharmaceuticals Submits IND Application to US FDA for QRX003	MT
05-07	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-28	Quoin Pharmaceuticals provides clinical and regulatory update for QRX009 topical rapamycin development programs	RE
04-28	Quoin Pharmaceuticals Ltd Provides Clinical And Regulatory Update For QRX009 Topical Rapamycin Development Programs	CI
03-26	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-25	Quoin Pharmaceuticals, Ltd. Auditor Raises 'Going Concern' Doubt	CI
03-25	Quoin Pharmaceuticals provides clinical and regulatory update from constructive type C meeting with U.S. FDA for QRX003 in Netherton syndrome	RE
03-25	Quoin Pharmaceuticals Ltd. Provides Clinical and Regulatory Update for Qrx003 in Netherton Syndrome	CI
03-11	Quoin Pharmaceuticals Ltd. Announces FDA Grants Fast Track Designation For QRX003 For The Treatment Of Netherton Syndrome	CI
01-27	Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome	CI
01-20	Quoin, Inc. Announces Application for Breakthrough Medicine Designation with the SFDA for QRX003	CI
01-20	Quoin Pharmaceuticals files breakthrough medicine designation application in Saudi Arabia for QRX003 in Netherton syndrome	RE
12-05	Top Premarket Decliners	MT

Chart Quoin Pharmaceuticals, Ltd.

Duration

Period

QNRX: Dynamic Chart

Company Profile

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Companyâ€™s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Employees

Sector

Biotechnology & Medical Research

More about the company